The pandemic of COVID-19 infection caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) has posed a significant threat to global health. Now, we have witnessed an unsurpassed increase in the number of clinical trials worldwide. In clinical trials old and new drugs are tested as potential treatments either for their direct anti-viral activity, or for their ability to provide management of respiratory and cardiovascular symptoms and complications, characteristic of COVID-19. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Such a strategy is likely to give rise to a range of safety and efficacy challenges that could be addressed through preliminary pharmaco-genetic research on identification of risk groups for personification of therapy approach. Addressing the personification of drug treatment COVID-19 becomes an urgent need to interpret the conflicting results of clinical trials and establish the apparent efficacy of any particular drug.